Search
Powered By HealthLine
Health Tools
 Mood Tracker
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Study: IV Drugs May Not Improve Long-term Survival

Ivanhoe Broadcast News


(Ivanhoe Newswire) -- Patients with an out-of-hospital cardiac arrest who received intravenous (IV) drug administration had higher rates of short-term survival but no statistically significant improvement in survival to hospital discharge or long-term survival.

"Intravenous access and drug administration are integral parts of cardiopulmonary resuscitation (CPR) guidelines. Millions of patients have received epinephrine during advanced cardiac life support (ACLS) with little or no evidence of improved survival to hospital discharge," the authors were quoted as saying. "Epinephrine was an independent predictor of poor outcome in a large epidemiological study, possibly due to toxicity of the drug or CPR interruptions secondary to establishing an intravenous line and drug administration."
 
Theresa M. Olasveengen, M.D., of Oslo University Hospital, Norway, and colleagues compared outcomes for patients receiving standard ACLS with and without intravenous drug administration during out-of-hospital cardiac arrest in Oslo between May 2003 and April 2008. Of 1,183 patients for whom resuscitation was attempted, 851 were included in the study. A total of 418 patients received ACLS with intravenous drug administration, and 433 received ACLS with no intravenous drug administration.

Text Continues Below



Both groups had adequate and similar CPR quality, with few chest compression pauses and with compression and ventilation rates within the guideline recommendations.

"In the intravenous group, 44 of 418 patients survived to hospital discharge vs. 40 of 433 in the no intravenous group. Survival with favorable neurological outcome was 9.8 percent for the intravenous group and 8.1 percent for the no intravenous group," the authors wrote. "The cumulative postcardiac arrest survival rate at 7 days was 14.6 percent for patients in the intravenous group vs. 12.8 percent for patients in the no intravenous group, 11.3 percent vs. 8.8 percent, respectively, at 1 month, and 9.8 percent vs. 8.4 percent at 1 year."

The researchers note that after adjustment for ventricular fibrillation, response interval, witnessed arrest, or arrest in a public location, there was no significant difference in survival to hospital discharge for the intravenous group vs. the no intravenous group.

SOURCE: Journal of the American Medical Association (JAMA), November 25, 2009



If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Melissa Medalie at mmedalie@ivanhoe.com

This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.




Last updated 11/26/2009

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake





HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2012. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire